LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 221

Search options

  1. Book ; Online: Multiple Sclerosis: Perspectives in Treatment and Pathogenesis

    Zagon, Ian S / McLaughlin, Patricia J

    2017  

    Keywords MJN ; Multiple Sclerosis
    Language 0|e
    Size 1 electronic resource (187 pages)
    Publisher Exon Publications
    Publishing place Australia
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021608981
    ISBN 9780994438133 ; 0994438133
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Article ; Online: Opioid growth factor receptor: Anatomical distribution and receptor colocalization in neurons of the adult mouse brain.

    Kareem, Zainab Y / McLaughlin, Patricia J / Kumari, Rashmi

    Neuropeptides

    2023  Volume 99, Page(s) 102325

    Abstract: The opioid growth factor (OGF) is an endogenous peptide that binds to the nuclear-associated receptor (OGFr), and plays a significant role in the proliferation of developing, renewing, and healing tissues. The receptor is widely expressed in a variety of ...

    Abstract The opioid growth factor (OGF) is an endogenous peptide that binds to the nuclear-associated receptor (OGFr), and plays a significant role in the proliferation of developing, renewing, and healing tissues. The receptor is widely expressed in a variety of organs, however its distribution in the brain remains unknown. In this study, we investigated the distribution of OGFr in different brain regions of male heterozygous (-/+ Lepr
    MeSH term(s) Animals ; Male ; Mice ; Brain/metabolism ; Diabetes Mellitus, Experimental ; Neurons/metabolism ; Receptors, Opioid/physiology
    Chemical Substances methionine-enkephalin receptor ; Receptors, Opioid
    Language English
    Publishing date 2023-02-15
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 9048-7
    ISSN 1532-2785 ; 0143-4179
    ISSN (online) 1532-2785
    ISSN 0143-4179
    DOI 10.1016/j.npep.2023.102325
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Acute Low Dose Naltrexone Increases β-Endorphin and Promotes Neuronal Recovery Following Hypoxia-Ischemic Stroke in Type-2 Diabetic Mice.

    Kumari, Rashmi / Kareem, Zainab Y / McLaughlin, Patricia J

    Neurochemical research

    2023  Volume 48, Issue 9, Page(s) 2835–2846

    Abstract: Diabetic patients experience significant mortality and poor recovery following ischemic stroke. Our clinical and basic science studies demonstrate an overall immune suppression in the periphery of diabetic stroke patients, as well as within the central ... ...

    Abstract Diabetic patients experience significant mortality and poor recovery following ischemic stroke. Our clinical and basic science studies demonstrate an overall immune suppression in the periphery of diabetic stroke patients, as well as within the central nervous system (CNS) of type-2 diabetic mice following hypoxia-ischemia (HI). Low doses of naltrexone (LDN) improved clinical outcomes in many autoimmune diseases by acting on opioid receptors to release β-endorphin which in turn balances inflammatory cytokines and modulates the opioid growth factor (OGF)-opioid growth factor receptor (OGFr) pathway. We hypothesized that in our model of diabetic mice, LDN treatment will induce the release of β-endorphin and improve CNS response by promoting neuronal recovery post HI. To test this hypothesis, we induced HI in 10 week old male db/db and db/ + mice, collected tissue at 24 and 72 h post HI, and measured OGF levels in plasma and brain tissue. The infarct size and number of OGF + neurons in the motor cortex, caudate and hippocampus (CA3) were measured. Following HI, db/db mice had significant increases in brain OGF expression, increased infarct size and neurological deficits, and loss of OGFr + neurons in several different brain regions. In the second experiment, we injected LDN (1 mg/kg) intraperitoneally into db/db and db/ + mice at 4, 24, and 48 h post HI, and collected brain tissue and blood at 72 h. Acute LDN treatment increased β-endorphin and OGF levels in plasma and promoted neuronal recovery in db/db mice compared to phosphate buffer saline (PBS)-treated diabetic mice suggesting a protective or regenerative effect of LDN.
    MeSH term(s) Animals ; Male ; Mice ; beta-Endorphin ; Diabetes Mellitus, Experimental/complications ; Diabetes Mellitus, Type 2/complications ; Ischemic Stroke/drug therapy ; Ischemic Stroke/ethnology ; Naltrexone/pharmacology ; Naltrexone/therapeutic use ; Neurons
    Chemical Substances beta-Endorphin (60617-12-1) ; Naltrexone (5S6W795CQM)
    Language English
    Publishing date 2023-05-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 199335-5
    ISSN 1573-6903 ; 0364-3190
    ISSN (online) 1573-6903
    ISSN 0364-3190
    DOI 10.1007/s11064-023-03938-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Safety study of topical naltrexone therapy for diabetic skin wounds is confirmed in Göttingen mini-pigs.

    McLaughlin, Patricia J / Sassani, Joseph W / Zagon, Ian S

    Drug development research

    2023  Volume 84, Issue 6, Page(s) 1279–1284

    Abstract: This study was conducted to determine the safety of topical naltrexone treatment in Göttingen swine. Efficacy of topical naltrexone was performed previously in Sprague-Dawley rats. In this study, 25 male and female mini-pigs received topical naltrexone ... ...

    Abstract This study was conducted to determine the safety of topical naltrexone treatment in Göttingen swine. Efficacy of topical naltrexone was performed previously in Sprague-Dawley rats. In this study, 25 male and female mini-pigs received topical naltrexone once daily for 30 days. The gel at doses of 1%, 2%, and 10% naltrexone was applied at a dose volume of 0.01 ml/cm
    MeSH term(s) Rats ; Male ; Animals ; Female ; Swine ; Naltrexone ; Narcotic Antagonists/adverse effects ; Swine, Miniature ; Rats, Sprague-Dawley ; Diabetes Mellitus, Experimental/drug therapy
    Chemical Substances Naltrexone (5S6W795CQM) ; Narcotic Antagonists
    Language English
    Publishing date 2023-06-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604587-x
    ISSN 1098-2299 ; 0272-4391
    ISSN (online) 1098-2299
    ISSN 0272-4391
    DOI 10.1002/ddr.22086
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Dysregulation of the OGF-OGFr pathway and associated diabetic complications.

    McLaughlin, Patricia J / Sassani, Joseph W / Zagon, Ian S

    Journal of diabetes and clinical research

    2022  Volume 3, Issue 3, Page(s) 64–67

    Abstract: Background: Diabetes is a worldwide epidemic with more than 550 million individuals expected to be diagnosed with the disease by 2030. Complications associated with diabetes affect nearly all systems, but more than 54% of diabetic individuals have ... ...

    Abstract Background: Diabetes is a worldwide epidemic with more than 550 million individuals expected to be diagnosed with the disease by 2030. Complications associated with diabetes affect nearly all systems, but more than 54% of diabetic individuals have ocular surface disorders including keratopathy, dry eye or altered corneal surface sensitivity, and nearly 70% experience slow healing foot ulcers which if left untreated, can lead to amputation. There is new information regarding the underlying pathophysiology associated with these complications, as well as potential treatment.
    Aim: This commentary assembles data on preclinical studies showing that corneal surface complications such as dry eye and sensitivity, as well as delayed epithelial wound healing in the cornea and skin in diabetic rats and mice, correlate with a dysregulation of the opioid growth factor (OGF)-opioid growth factor receptor (OGFr) regulatory axis. The peptide in this pathway, OGF, chemically termed [Met
    Summary: Dysfunction of the OGF-OGFr growth regulatory system plays a role in the development of ocular surface complications and delayed cutaneous wound healing complications in multiple animal models of both Type 1 and Type 2 diabetes. Modulation of this system may hold promise for reversing or even preventing these diabetic complications in humans. Moreover, monitoring serum levels of OGF should be investigated as an indicator of the development of these and other diabetic complications.
    Language English
    Publishing date 2022-02-28
    Publishing country United States
    Document type Journal Article
    ISSN 2689-2839
    ISSN (online) 2689-2839
    DOI 10.33696/diabetes.3.041
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Sex Differences in Diabetic Ocular Surface Complications and Dysregulation of the OGF-OGFr Pathway.

    Zagon, Ian S / Sassani, Joseph W / McLaughlin, Patricia J

    Journal of diabetes and clinical research

    2022  Volume 4, Issue 1, Page(s) 20–24

    Abstract: Background: Diabetes is a chronic disorder that affects more than 500 million individuals worldwide. It is a life-long disease with complications that attack nearly all other systems within the body. Although there is a slight increase in the prevalence ...

    Abstract Background: Diabetes is a chronic disorder that affects more than 500 million individuals worldwide. It is a life-long disease with complications that attack nearly all other systems within the body. Although there is a slight increase in the prevalence of diabetes in males, ocular surface complications are equally present in males and females.
    Aim: This review provides a discussion on preclinical studies related to the dysregulation of a biological pathway that appears to be causally related to diabetic ocular surface complications including dry eye, delayed corneal epithelial healing, and decreased corneal sensitivity. Most basic science and clinical studies focus on male sex in animal models in order to avoid confounders related to hormonal cycling. However, with approximately 10.2% of all women in the US aged 18-44 being diagnosed with diabetes and nearly 4% additional women having undiagnosed disease, it is prudent to examine the onset of these dysregulations also in females and to note any sex-related differences in the timing of onset or severity of ocular surface complications.
    Summary: Data from several well-controlled investigations have documented that female rats with type 1 diabetes develop ocular surface complications before male rats. In part, this finding may be due to the increase in the inhibitory peptide Opioid Growth Factor (OGF) that occurs within 2 weeks of the induction of hyperglycemia in female animals in comparison to the changes in OGF levels in male rats which occur at 4 weeks. It was noted that estrogen levels drop within weeks of induction of hyperglycemia and could serve as another marker for the onset of disease activity and/or its complications. Finally, insulin does not appear to protect against early changes in OGF levels or estrogen secretion in diabetic female rats, setting the stage for a distinction in the disease profile of diabetes between males and females. These data encourage further studies on both sexes in order to establish a complete understanding of the underlying pathologies associated with complications associated with diabetes.
    Language English
    Publishing date 2022-05-13
    Publishing country United States
    Document type Journal Article
    ISSN 2689-2839
    ISSN (online) 2689-2839
    DOI 10.33696/diabetes.4.052
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats.

    McLaughlin, Patricia J / Sassani, Joseph W / Diaz, David / Zagon, Ian S

    Journal of diabetes and clinical research

    2022  Volume 5, Issue 1, Page(s) 1–10

    Abstract: Ocular surface complications occur in more than 50% of individuals diagnosed with diabetes. The financial and health-related burden of diabetes is increasing annually. Several major ocular complications associated with diabetes involve the limbus. The ... ...

    Abstract Ocular surface complications occur in more than 50% of individuals diagnosed with diabetes. The financial and health-related burden of diabetes is increasing annually. Several major ocular complications associated with diabetes involve the limbus. The vascular limbus, adjacent to the avascular cornea, is the source of circulating growth factors, elevated glucose, and cytokines for the cornea. The Opioid Growth Factor (OGF) - Opioid OGF Receptor (OGFr) axis is comprised of its effector peptide, OGF, [Met
    Language English
    Publishing date 2022-06-03
    Publishing country United States
    Document type Journal Article
    ISSN 2689-2839
    ISSN (online) 2689-2839
    DOI 10.33696/diabetes.4.054
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Ocular surface complications result from dysregulation of the OGF-OGFr signaling pathway in female diabetic rats.

    Purushothaman, Indira / Zagon, Ian S / Sassani, Joseph W / Mclaughlin, Patricia J

    Experimental and therapeutic medicine

    2021  Volume 22, Issue 1, Page(s) 687

    Abstract: Approximately 4.5 million women in the United States exhibit diabetes-associated ocular complications. The time course and magnitude of these complications, and their association with the dysregulation of the opioid growth factor (OGF)-OGF receptor (OGFr) ...

    Abstract Approximately 4.5 million women in the United States exhibit diabetes-associated ocular complications. The time course and magnitude of these complications, and their association with the dysregulation of the opioid growth factor (OGF)-OGF receptor (OGFr) signaling pathway are unknown. The present study investigated the onset and magnitude of ocular surface complications and the association with a dysregulated OGF-OGFr signaling pathway in diabetic female rats. Adult female Sprague-Dawley rats were injected with streptozotocin in order to establish a model of type 1 diabetes (T1D), and a subset received insulin (T1D-INS). Blood glucose, body weight, tear production and corneal sensitivity, as well as serum and tissue expression levels of OGF and OGFr, were assessed. Corneal epithelial wound healing was also evaluated. In a second study, female T1D rats were treated with topical naltrexone (NTX) to determine whether blockade of the OGF-OGFr signaling pathway by NTX altered development of corneal surface complications. Female T1D rats had elevated glucose levels and reduced body weight compared with control and T1D-INS rats. In both diabetic groups, tear production was decreased within 2 weeks and corneal sensitivity was decreased 2.5-fold within 5 weeks, while corneal epithelial wound healing was delayed only in T1D rats. Serum and tissue levels of OGF and OGFr were elevated in diabetes. Twice daily NTX treatment reversed most ocular surface complications in the diabetic female rats. The present data demonstrated a seminal discovery in female T1D rats, in which the onset and magnitude of diabetes-associated ocular surface complications were associated with dysregulation of the OGF-OGFr regulatory pathway. Blockade of the OGF-OGFr pathway with the opioid receptor antagonist NTX prevented the onset and/or decreased the magnitude of these deficits. The current data support the need for translational research on this therapeutic approach for diabetic human subjects.
    Language English
    Publishing date 2021-04-28
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 2683844-8
    ISSN 1792-1015 ; 1792-0981
    ISSN (online) 1792-1015
    ISSN 1792-0981
    DOI 10.3892/etm.2021.10119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Naltrexone as a Novel Therapeutic for Diabetic Corneal Complications.

    McLaughlin, Patricia J / Sassani, Joseph W / Zagon, Ian S

    Journal of cellular immunology

    2020  Volume 2, Issue 2, Page(s) 42–46

    Abstract: Diabetes is a widespread autoimmune disorder that affects nearly 10% of the adult population in the United States. In addition to the primary disease, there are numerous complications associated with inflammation including abnormalities of the heart, ... ...

    Abstract Diabetes is a widespread autoimmune disorder that affects nearly 10% of the adult population in the United States. In addition to the primary disease, there are numerous complications associated with inflammation including abnormalities of the heart, visual system, and peripheral nervous system. More than half of the individuals with diabetes will have one or more ocular related complications such as dry eye disease (DED), keratopathy, or retinopathy. Research over the last 3 decades has focused on the role of the opioid growth factor - opioid growth factor receptor (OGF-OGFr) axis as a regulatory system that maintains homeostasis in corneal epithelialization and tear secretion. In diabetes, OGF appears to be dysregulated resulting in decreased cell replication and increased corneal surface sensitivity. Utilization of naltrexone as a topical therapeutic to block the OGF-OGFr axis results in reversal of dry eye and restoration of corneal sensitivity and rates of corneal re-epithelialization. Naltrexone treatment at dosages that are substantially lower than systemically approved doses appear to be safe and effective therapy for corneal surface abnormalities associated with diabetes.
    Language English
    Publishing date 2020-05-03
    Publishing country United States
    Document type Journal Article
    ISSN 2689-2812
    ISSN (online) 2689-2812
    DOI 10.33696/immunology.1.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Top 10 research priorities for digital technology for adolescents and young persons with inflammatory bowel disease: Results of a James Lind Alliance Priority Setting Partnership.

    Narula, Priya / Gasparetto, Marco / Wong, Charlotte / Branchflower, Jacob / Sebastian, Shaji / McLaughlin, John / Rao, Arati / Wakeman, Ruth / Ainley, Rachel / Smith, Philip J / Kammermeier, Jochen / Younge, Lisa / Randall, Sophie / Bukhari, Seema / Manson, Jess / Ellis, Patricia / Arebi, Naila

    Journal of pediatric gastroenterology and nutrition

    2024  Volume 78, Issue 3, Page(s) 670–676

    Abstract: Objectives: Priority Setting Partnerships (PSP's) using the James Lind Alliance (JLA) methodology, bring together health professionals, patients and parents/carers to identify and prioritise unanswered questions that can be addressed by future research ... ...

    Abstract Objectives: Priority Setting Partnerships (PSP's) using the James Lind Alliance (JLA) methodology, bring together health professionals, patients and parents/carers to identify and prioritise unanswered questions that can be addressed by future research projects. To identify and prioritise the top 10 unanswered research priorities in digital technology for adolescents and young people (AYP) with inflammatory bowel disease (IBD).
    Methods: A steering group (SG) consisting of AYP with IBD, their parents/carers, representatives from two charities (Crohn's & Colitis UK, Crohn's in Childhood Research Association), patient information forum and paediatric and adult and primary care healthcare professionals was established in 2021. The SG agreed the protocol, and scope of the PSP and oversaw all aspects. SG meetings were chaired by a JLA advisor and followed the established JLA methodology.
    Results: The initial survey generated 414 in-scope questions from 156 respondents, thematically categorised into 10 themes and consolidated into 92 summary questions by the SG. A comprehensive literature review followed by SG deliberation narrowed the unanswered summary questions to 45, for the interim prioritising survey. One hundred and two respondents ranked their top 10 research questions. Outputs generated top 18 research priorities presented at a final virtual prioritisation workshop, facilitated by JLA advisors and attended by key stakeholders, ranked into top 10 research priorities.
    Discussion: The top 10 research priorities will encourage researchers to undertake research that addresses these areas of unmet need for AYP living with IBD, their parents/carers and their healthcare professionals, thereby facilitating improved patient care.
    MeSH term(s) Adult ; Humans ; Adolescent ; Child ; Digital Technology ; Health Priorities ; Cooperative Behavior ; Surveys and Questionnaires ; Research ; Inflammatory Bowel Diseases/therapy ; Biomedical Research
    Language English
    Publishing date 2024-01-04
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 603201-1
    ISSN 1536-4801 ; 0277-2116
    ISSN (online) 1536-4801
    ISSN 0277-2116
    DOI 10.1002/jpn3.12105
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top